cspc pharmaceutical group ltd. - CHJTF

CHJTF

Close Chg Chg %
0.95 -0.00 -0.00%

Closed Market

0.95

0.00 (0.00%)

Volume: 5.05K

Last Updated:

Nov 12, 2025, 9:30 AM EDT

Company Overview: cspc pharmaceutical group ltd. - CHJTF

CHJTF Key Data

Open

$0.95

Day Range

0.95 - 0.95

52 Week Range

0.54 - 1.28

Market Cap

$11.06B

Shares Outstanding

11.52B

Public Float

7.83B

Beta

0.75

Rev. Per Employee

N/A

P/E Ratio

20.73

EPS

$0.02

Yield

320.26%

Dividend

$0.02

EX-DIVIDEND DATE

Oct 17, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

1.17K

 

CHJTF Performance

No Data Available

CHJTF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About cspc pharmaceutical group ltd. - CHJTF

CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Shijiazhuang, China.

CHJTF At a Glance

CSPC Pharmaceutical Group Ltd.
No.896 Zhongshandong Street
Shijiazhuang, Hebei 050035
Phone 86-311-8703-7015 Revenue 4.03B
Industry Biotechnology Net Income 601.38M
Sector Health Technology Employees 21,400
Fiscal Year-end 12 / 2025
View SEC Filings

CHJTF Valuation

P/E Current 20.732
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 12.019
Price to Sales Ratio 1.792
Price to Book Ratio 1.62
Price to Cash Flow Ratio 10.85
Enterprise Value to EBITDA 6.866
Enterprise Value to Sales 1.583
Total Debt to Enterprise Value 0.011

CHJTF Efficiency

Revenue/Employee 188,357.229
Income Per Employee 28,101.953
Receivables Turnover 2.947
Total Asset Turnover 0.639

CHJTF Liquidity

Current Ratio 2.272
Quick Ratio 1.947
Cash Ratio 0.856

CHJTF Profitability

Gross Margin 69.973
Operating Margin 18.453
Pretax Margin 19.539
Net Margin 14.919
Return on Assets 9.54
Return on Equity 13.214
Return on Total Capital 13.394
Return on Invested Capital 13.181

CHJTF Capital Structure

Total Debt to Total Equity 1.572
Total Debt to Total Capital 1.548
Total Debt to Total Assets 1.143
Long-Term Debt to Equity 0.174
Long-Term Debt to Total Capital 0.171
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cspc Pharmaceutical Group Ltd. - CHJTF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
4.32B 4.59B 4.44B 4.03B
Sales Growth
+19.57% +6.33% -3.38% -9.19%
Cost of Goods Sold (COGS) incl D&A
1.04B 1.29B 1.31B 1.21B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
133.93M 155.31M 157.26M 185.66M
Depreciation
130.00M 141.89M 145.56M 164.94M
Amortization of Intangibles
3.93M 13.42M 11.69M 20.71M
COGS Growth
+15.14% +23.50% +1.53% -7.53%
Gross Income
3.28B 3.31B 3.13B 2.82B
Gross Income Growth
+21.05% +0.86% -5.30% -9.89%
Gross Profit Margin
+75.84% +71.94% +70.51% +69.97%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.31B 2.30B 2.14B 2.08B
Research & Development
532.24M 592.02M 681.77M 721.24M
Other SG&A
1.78B 1.71B 1.46B 1.36B
SGA Growth
+20.26% -0.50% -6.76% -3.05%
Other Operating Expense
- - - -
-
Unusual Expense
(36.68M) (21.72M) 23.40M 14.52M
EBIT after Unusual Expense
1.01B 1.03B 964.73M 729.31M
Non Operating Income/Expense
54.36M 102.29M 89.54M 64.36M
Non-Operating Interest Income
28.41M 36.02M 36.68M 32.31M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.19M 3.70M 3.66M 6.07M
Interest Expense Growth
-32.94% +211.06% -1.12% +66.03%
Gross Interest Expense
1.19M 3.70M 3.66M 6.07M
Interest Capitalized
- - - -
-
Pretax Income
1.06B 1.13B 1.05B 787.60M
Pretax Income Growth
+14.53% +6.63% -6.89% -25.03%
Pretax Margin
+24.49% +24.56% +23.67% +19.54%
Income Tax
179.70M 200.52M 185.84M 172.28M
Income Tax - Current - Domestic
151.21M 196.40M 199.82M 200.77M
Income Tax - Current - Foreign
1.05M 1.93M 1.59M 846.90K
Income Tax - Deferred - Domestic
27.44M 2.19M (15.57M) (29.33M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
881.97M 925.50M 857.12M 602.88M
Minority Interest Expense
12.86M 20.89M 28.14M 1.50M
Net Income
869.11M 904.61M 828.98M 601.38M
Net Income Growth
+16.26% +4.09% -8.36% -27.45%
Net Margin Growth
+20.11% +19.69% +18.68% +14.92%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
869.11M 904.61M 828.98M 601.38M
Preferred Dividends
- - - -
-
Net Income Available to Common
869.11M 904.61M 828.98M 601.38M
EPS (Basic)
0.0727 0.0759 0.0698 0.0512
EPS (Basic) Growth
+16.32% +4.40% -8.04% -26.65%
Basic Shares Outstanding
11.95B 11.92B 11.87B 11.74B
EPS (Diluted)
0.0727 0.0759 0.0698 0.0512
EPS (Diluted) Growth
+16.32% +4.40% -8.04% -26.65%
Diluted Shares Outstanding
11.95B 11.92B 11.87B 11.74B
EBITDA
1.10B 1.16B 1.15B 929.48M
EBITDA Growth
+21.90% +5.54% -1.54% -18.85%
EBITDA Margin
+25.51% +25.32% +25.80% +23.06%

Cspc Pharmaceutical Group Ltd. in the News